Skin Care and Cosmetic Composition

Abstract

A skin care composition and product having beneficial effects on skin conditions/symptoms, such as reducing wrinkles and skin roughness and improving skin elasticity, etc. The composition has three separate parts: a powder part, an aqueous part and an emulsion part. The power part comprises Oligopeptide-1 and Ginseng saponin. The aqueous part comprises Glycyrrhiza glabra Root Extract, Artemisia capillaris Flower Extract, Radix Mori Albae Extract, Zizyphus jujuba Fruit Extract, Scutellaria baicalensis Root Extract, hydrolyzed rice protein and nicotinamide. The emulsion part comprises Bifida ferment lysate, creatine, carnosine, Glucosyl Hesperidin, Hexapeptide-3, Centella asiatica Extract, Coenzyme Q10 capsule, Opuntia Ficus-indica Stem Extract, Rhodiola rosea Extract, Saussurea Involucrata Extract, Panax notoginseng Root Extract and Angelica sinensis Extract capsule.

Claims

1. An skin care composition, comprising three part being a powder part, an aqueous part and an emulsion part, each part in a separate containers, wherein: said powder part comprises the following ingredients in specified portions by weight: TABLE-US-00035 Oligopeptide-1 0~1.0 portion.sup.  Ginseng saponin 0~5.0 portions provided that at least one of the ingredients must be present; said aqueous part comprises the following ingredients in specified portions by weight: TABLE-US-00036 Glycyrrhiza glabra Root Extract 0~3.0 portions Artemisia capillaris Flower Extract 0~3.0 portions Radix Mori Albae Extract 0~2.0 portions Zizyphus jujuba Fruit Extract 0~2.0 portions Scutellaria baicalensis Root Extract 0~2.0 portions hydrolyzed rice protein 0~5.0 portions nicotinamide 0~3.0 portions provided that at least one of the ingredients must be present; and said emulsion part comprises the following ingredients in specified portions by weight: TABLE-US-00037 Bifida ferment lysate 0.5~10.0 portions   creatine 0~2.0 portions carnosine 0~2.0 portions Glucosyl Hesperidin 0~5.0 portions Hexapeptide-3 0~5.0 portions Centella asiatica Extract 0~3.0 portions Coenzyme Q10 capsule 0~2.0 portions Opuntia Ficus-indica Stem Extract 0~5.0 portions Rhodiola rosea Extract 0~2.0 portions Saussurea Involucrata Extract 0~5.0 portions Panax notoginseng Root Extract 0~5.0 portions Angelica sinensis Extract capsule 0~5.0 portions provided that Bifida ferment lysate and at least one other ingredient must be present.

2. The skin care composition of claim 1, wherein: said powder part is: TABLE-US-00038 Oligopeptide-1 0.01~0.5 portion .sup.  Ginseng saponin 0.1~2.0 portions.

3. The skin care composition of claim 2, wherein: said powder part is: TABLE-US-00039 Oligopeptide-1 0.01~0.05 portion  Ginseng saponin 0.10~0.50 portion.

4. The skin care composition of claim 1, wherein: said aqueous part is: TABLE-US-00040 Glycyrrhiza glabra Root Extract 0.10~1.50 portions Artemisia capillaris Flower Extract 0.10~1.50 portions Radix Mori Albae Extract 0.10~1.00 portion.sup.  Zizyphus jujuba Fruit Extract 0.10~1.00 portion.sup.  Scutellaria baicalensis Root Extract 0.10~1.00 portion.sup.  hydrolyzed rice protein 0.10~2.00 portions nicotinamide  0.10~1.50 portions.

5. The skin care composition of claim 4, wherein: said aqueous part is: TABLE-US-00041 Glycyrrhiza glabra Root Extract 0.5~1.0 portion Artemisia capillaris Flower Extract 0.5~1.0 portion Radix Mori Albae Extract 0.5~1.0 portion Zizyphus jujuba Fruit Extract 0.5~1.0 portion Scutellaria baicalensis Root Extract 0.5~1.0 portion hydrolyzed rice protein 0.5~1.0 portion nicotinamide 0.50~1.0 portion. 

6. The skin care composition of claim 1, wherein: said emulsion part is: TABLE-US-00042 Rhodiola rosea Extract 0.1~2.0 portions Bifida ferment lysate 0.5~5.0 portions creatine 0.5~1.5 portions carnosine 0.1~1.0 portion.sup.  Glucosyl Hesperidin 0.1~2.0 portion.sup.  Hexapeptide-3 0.5~1.5 portions Centella asiatica Extract 0.1~1.0 portion.sup.  Coenzyme Q10 capsule 0.1~1.0 portion.sup.  Opuntia Ficus-indica Stem Extract  0.1~3.0 portions.

7. The skin care composition of claim 1, wherein said emulsion is of lotion, gel or cream.

8. The skin care composition of claim 1, wherein said powder part further comprises an external dosage form matrix with one or more ingredients selected from the group consisting of mannitol, disodium hydrogen phosphate and sodium dihydrogen phosphate.

9. The skin care composition of claim 1, wherein said aqueous part further comprises an external dosage form matrix with one or more ingredients selected from the group consisting sodium hyaluronate, oxhide glue, butanediol, disodium EDTA, dipotassium glycyrrhetate, panthenol and preservatives.

10. The skin care composition of claim 7, wherein said emulsion part further comprises an external dosage form matrix with one or more ingredients selected from the group consisting bisabolol, cetylhydroxyproline palmitamide, brassica campestris sterol, jojoba seed oil, phytosterol isostearate, Vitamin E acetate, silicone oil, cetyl stearyl alcohol, sucrose polystearate, Beheneth-25, dipalmitoyl hydroxyproline, Acrylates/C10-30 alkyl acrylate crosspolymer, butanediol, glycerin, sodium stearoyl glutamate, disodium EDTA, xanthan gum, deionized water, acrylamide/ammonia acrylate copolymer-Poly(isobutylene)-Polysorbate-20, 1-methylhydantoin-2-imide and preservatives.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0034] FIG. 1 shows the overall effect of the skin care product of two particular embodiments on volunteers participated in a trial in comparison with a comparative products available in the prior art.

[0035] FIG. 2 shows the effects on specific skin conditions in the same trial as FIG. 2 of two particular embodiments and a comparative products available in the prior art.

[0036] The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages, and specific objects attained by its use, reference should be made to the drawings and the following description in which there are illustrated and described preferred embodiments of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0037] The present invention will be further described as follows in combination with specific embodiments, but the embodiments shall not restrict the present invention in any forms. The material and ingredients used in the embodiments are all commercially available. Unless specifically addressed, the portion number of each ingredient in the following description is weight portion.

Embodiment 1

1. Preparation of the Powder Part:

[0038] The ingredients are:

TABLE-US-00009 Oligopeptide-1 0.1 portion; Ginseng saponin 1.0 portion; mannitol 10.0 portions;.sup.  disodium hydrogen phosphate 0.5 portion; sodium dihydrogen phosphate 0.2 portion.

[0039] The preparation process is as follows:

[0040] (1) Dissolve all the components in an appropriate amount of deionized water, and filter the resulting solution through a 0.2 μm membrane.

[0041] (2) Fill it into small glass vials, and place the vials into a vacuum freeze drier.

[0042] (3) Vacuum dry for 45 hours so that it is in the form of powder.

2. Preparation of Aqueous Part:

[0043] The ingredients are:

TABLE-US-00010 Glycyrrhiza glabra Root Extract 2.0 portions; Artemisia capillaris Flower Extract 2.0 portions; Radix Mori Albae Extract 1.0 portion; Zizyphus jujuba Fruit Extract 1.0 portion; Scutellaria baicalensis Root Extract 1.0 portion; hydrolyzed rice protein 3.0 portions; nicotinamide 2.0 portions; sodium hyaluronate 0.5 portion; butanediol 10.0 portions; disodium EDTA 0.5 portion; dipotassium glycyrrhetate 1.0 portion; panthenol 5.0 portions; preservatives 0.1 portion; deionized water in an appropriate amount.

[0044] The molecular weight of the sodium hyaluronate is 300,000.

[0045] The preparation process is as follows:

[0046] (1) Add sodium hyaluronate to the deionized water, and stir to dissolve.

[0047] (2) Add all other components and stir to dissolve.

[0048] (3) Adjust the resulting solution to pH 5.5˜7.0, and passing quality examination fill it into small vials.

3. Preparation of a Lotion Part

[0049] The ingredients are:

Phase A:

[0050]

TABLE-US-00011 jojoba seed oil 8 portions; phytosterol isostearate 5 portions; Vitamin E acetate 3 portions; Rhodiola rosea Extract 0.1 portion; .sup.  Palmitoyl hydrolyzed wheat protein 3 portions; Cetyl stearyl alcohol 2 portions; Sucrose polystearate 2 portions; hydrogenated Poly(isobutylene) 5 portions; Dipalmitoyl hydroxyproline 2 portions;

Phase B:

[0051]

TABLE-US-00012 Acrylates/C10-30 alkyl acrylate crosspolymer 0.5 portion; butanediol 10 portions; glycerin 5 portions; Sodium stearoyl glutamate 1 portion; disodium EDTA 0.1 portion; xanthan gum 0.5 portion; deionized water margin;

Phase C:

[0052] acrylamide/ammonia acrylate copolymer (and) Poly(isobutylene) 2.0 portions; (and) Polysorbate-20

Phase D:

[0053]

TABLE-US-00013 aminomethyl propanol 0.2 portion 1-methylhydantoin-2-imide 1.0 portion; creatine 0.5 portion; carnosine 0.5 portion; Glucosyl Hesperidin 1.0 portion; dipotassium glycyrrhetate 2.0 portions; Bifida ferment lysate 5.0 portions; Hexapeptide-3 0.5 portion Centella asiatica Extract 1.0 portion; Coenzyme Q10 capsule 1.0 portion; Opuntia Ficus-indica Stem Extract 2.0 portions; Saussurea Involucrata Extract 0.5 portion; Panax notoginseng Root Extract 0.5 portion; Angelica sinensis Extract capsule 0.5 portion; preservatives 0.1 portion.

[0054] The preparation process is as follows:

[0055] (1) All components in Phase A are mixed evenly, heated to 80° C., stirred to dissolve to obtain Phase A solution;

[0056] (2) Acrylates/C10-30 alkyl acrylate crosspolymer is added to deionized water, stirred to dissolve, then other raw materials in Phase B are added, heated to 80° C., stirred to dissolve to obtain Phase B solution;

[0057] (3) Phase A solution is added to Phase B solution, and then all components in Phase C are added, stirred to homogenize to be emulsified;

[0058] (4) The mixture is stirred and cooled to 45° C., aminomethyl propanol is added, stirred to dissolve, and then other raw materials in Phase D are added, stirred and cooled to 30˜35° C.;

[0059] (5) A lotion is obtained, whose pH value is adjusted to 5.5˜6.5, upon passing quality examination, filled to the vessels.

Embodiment 2

1. Preparation of Powder Part

[0060] The ingredients are:

TABLE-US-00014 Oligopeptide-1 0.5 portion; Ginseng saponin 2.0 portions; mannitol  15 portions; disodium hydrogen phosphate 0.5 portion; sodium dihydrogen phosphate 0.2 g portion.

[0061] The preparation process is as follows:

[0062] (1) All components are dissolved in an appropriate amount of deionized water, then the obtained solution is filtered through a 0.2 μm membrane.

[0063] (2) The solution is loaded on to a plate which is put into a vacuum freeze drier.

[0064] (3) The solution is being vacuum dried for 45 hours into a form of powder, which is then distributed into small vials.

2. Preparation of Aqueous Part

[0065] The ingredients are:

TABLE-US-00015 Glycyrrhiza glabra Root Extract 0.5 portion Artemisia capillaris Flower Extract 0.5 portion Radix Mori Albae Extract 0.5 portion Zizyphus jujuba Fruit Extract 0.5 portion Scutellaria baicalensis Root Extract 0.5 portion hydrolyzed rice protein 1.0 portion sodium hyaluronate 0.5 portion butanediol 8.0 portions disodium EDTA 0.1 portion dipotassium glycyrrhetate 0.5 portion panthenol 0.5 portion nicotinamide 0.3 portion xanthan gum 1.2 portions preservatives 0.1 portion deionized water in an appropriate amount.

[0066] The molecular weight of the sodium hyaluronate is 300,000.

[0067] The preparation process is as follows:

[0068] (1) Xanthan gum is added to the deionized water, stirred to dissolve.

[0069] (2) All the other components are added to the solution of (1), stirred to dissolve.

[0070] (3) An aqueous formulation is obtained, which is adjusted to PH to 5.5˜6.5, and after passing the quality examination, filled into vessels.

3. Preparation of a Cream

[0071] The ingredients are:

Phase A:

[0072]

TABLE-US-00016 jojoba seed oil 5 portions phytosterol isostearate 2 portions Vitamin E acetate 5 portions Rhodiola rosea Extract 0.5 portion Cetyl stearyl alcohol 3 portions Sucrose polystearate 5 portions Dipalmitoyl hydroxyproline 2 portions

Phase B:

[0073]

TABLE-US-00017 Acrylates/C10-30 alkyl acrylate crosspolymer 1.5 portions butanediol 15 portions glycerin 15 portions Sodium stearoyl glutamate 0.5 portion disodium EDTA 0.1 portion xanthan gum 0.5 portion deionized water margin

Phase C:

[0074] acrylamide/ammonia acrylate copolymer (and) Poly(isobutylene) 2.0 portions; (and) Polysorbate-20

Phase D:

[0075]

TABLE-US-00018 aminomethyl propanol 0.15 portion 1-methylhydantoin-2-imide 1.0 portion creatine 0.5 portion carnosine 0.5 portion Glucosyl Hesperidin 1.0 portion dipotassium glycyrrhetate 2.0 portions Bifida ferment lysate 5.0 portions Hexapeptide-3 1.0 portion Centella asiatica Extract 1.0 portion Coenzyme Q10 capsule 1.0 portion Opuntia Ficus-indica Stem Extract 2.0 portions Saussurea Involucrata Extract 0.5 portion Panax notoginseng Root Extract 0.5 portion Angelica sinensis Extract capsule 0.5 portion preservatives 0.1 portion

[0076] The preparation is as follows:

[0077] (1) The components in Phase A are heated to 80˜90° C., stirred to dissolve.

[0078] (2) Acrylates/C10-30 alkyl acrylate crosspolymer is added to deionized water, stirred to dissolve, then other raw materials in Phase B are added, heated to 80˜90° C., stirred to dissolve.

[0079] (3) Phase A is added to Phase B, stirred to homogenize to be emulsified, and meanwhile, the raw materials in Phase C are added;

[0080] (4) The above mixture is stirred and cooled to 45° C., and aminomethyl propanol is added, stirred to dissolve, and then other raw materials in Phase D are added, stirred and cooled to 30˜35° C.;

[0081] (5) A cream is obtained, whose pH value is adjusted to 5.5˜7.0;

[0082] (6) Passing quality examination, the cream is then filled into vessels.

Example 3

1. Preparation of Powder Part

[0083] The ingredients are:

TABLE-US-00019 Oligopeptide-1 0.5 portion Ginseng saponin 2.0 portions mannitol margin;

[0084] The preparation process is as follows:

[0085] (1) All components are mixed evenly.

[0086] (2) The mixture are divided into small portions and filled into sachets.

2. Preparation of Aqueous Part

[0087] The ingredients are:

TABLE-US-00020 Glycyrrhiza glabra Root Extract 2.0 portions Artemisia capillaris Flower Extract 2.0 portions Radix Mori Albae Extract 1.0 portion Zizyphus jujuba Fruit Extract 1.0 portion Scutellaria baicalensis Root Extract 1.0 portion hydrolyzed rice protein 3.0 portions glycerin 10.0 portions disodium EDTA 0.1 portion dipotassium glycyrrhetate 2.0 portions panthenol 0.5 portion nicotinamide 1.0 portion Acrylates/C10-30 alkyl acrylate crosspolymer 1.0 portion aminomethyl propanol 0.15 portion preservatives 0.10 portion deionized water in an appropriate amount.

[0088] The molecular weight of the sodium hyaluronate is 300,000.

[0089] The preparation process is as follows:

[0090] (1) Acrylates/C10-30 alkyl acrylate crosspolymer is added to the deionized water, stirred to disperse, aminomethyl propanol is added, stirred to dissolve completely.

[0091] (2) All the other components are added to (1), stirred to dissolve.

[0092] (3) Adjusted pH to 5.5˜7.0.

[0093] (4) Upon passing quality control, fill it into vessels.

3. Preparation of a Gel

[0094] The ingredient are:

Phase A:

[0095]

TABLE-US-00021 Cetyl stearyl alcohol 2 portions Sucrose polystearate 2 portions Dipalmitoyl hydroxyproline 2 portions Rhodiola rosea Extract 0.1 portion

Phase B:

[0096] Acrylates/C10-30 alkyl acrylate crosspolymer 3 portions

TABLE-US-00022 butanediol  10 portions glycerin   5 portions disodium EDTA 0.1 portion xanthan gum 0.5 portion deionized water margin

Phase C:

[0097] acrylamide/ammonia acrylate copolymer (and) Poly(isobutylene) 2.0 portions; (and) Polysorbate-20

Phase D:

[0098]

TABLE-US-00023 aminomethyl propanol 0.3 portion creatine 0.5 portion carnosine 0.5 portion Glucosyl Hesperidin 1.0 portion dipotassium glycyrrhetate 2.0 portions Bifida ferment lysate 5.0 portions Hexapeptide-3 0.5 portion Centella asiatica Extract 1.0 portion Coenzyme Q10 capsule 1.0 portion Opuntia Ficus-indica Stem Extract 2.0 portions Saussurea Involucrata Extract 0.5 portion Panax notoginseng Root Extract 0.5 portion Angelica sinensis Extract capsule 0.5 portion preservatives 0.1 portion.

[0099] The preparation process is as follows:

[0100] (1) The raw materials in Phase A are heated to 80˜90° C., stirred to dissolve;

[0101] (2) Acrylates/C10-30 alkyl acrylate crosspolymer is added to deionized water, stirred to dissolve, then other raw materials in Phase B are added, heated to 80˜90° C., stirred to dissolve.

[0102] (3) Phase A is added to Phase B, stirred to homogenize to be emulsified, and meanwhile, the raw materials in Phase C are added;

[0103] (4) The above mixture is stirred and cooled to 45° C., aminomethyl propanol is added, stirred to dissolve, and then other raw materials in Phase D are added, stirred and cooled to 30˜35° C.;

[0104] (5) A gel is obtained, whose pH value is adjusted to 5.5˜7.0;

[0105] (6) Upon passing examination, the gel is then filled into vessels.

Example 4

1. Preparation of Powder Part

[0106] The ingredients are:

TABLE-US-00024 Oligopeptide-1 0.001 portion; Ginseng saponin 0.1 portion; mannitol 5.0 portions; disodium hydrogen phosphate 0.5 portion; sodium dihydrogen phosphate 0.2 portion.

[0107] The preparation process is as follows:

[0108] (1) All components are dissolved in an appropriate amount of deionized water, then the obtained solution is sterilized in an autoclave at 121° C., 0.1 Mpa for 30 mins.

[0109] (2) It is distributed into small glass vials, and then place them into a vacuum freeze drier.

[0110] (3) It is then vacuum dried for 45 hours into the form of powder, and then vials are capped.

2. Preparation of Aqueous Part

[0111] The ingredients are:

TABLE-US-00025 Glycyrrhiza glabra Root Extract 0.5 portion; Artemisia capillaris Flower Extract 0.5 portion; Radix Mori Albae Extract 0.3 portion; Zizyphus jujuba Fruit Extract 0.3 portion; Scutellaria baicalensis Root Extract 0.3 portion; hydrolyzed rice protein 1.0 portion; nicotinamide 0.5 portion; sodium hyaluronate 0.1 portion; butanediol 8.0 portions; disodium EDTA 0.1 portion; dipotassium glycyrrhetate 0.1 portion; panthenol 0.5 portion; preservatives 0.01 portion; deionized water in an appropriate amount.

[0112] The molecular weight of the sodium hyaluronate is 300,000.

[0113] The preparation process is as follows:

[0114] (1) Sodium hyaluronate is added to the deionized water, stirred to dissolve.

[0115] (2) Other components are added, stirred to dissolve.

[0116] (3) An aqueous part is obtained, whose pH value is adjusted to 5.5˜7.0, and upon passing quality control, filled into vials.

3. Preparation of a Lotion

[0117] The ingredients are:

Phase A:

[0118]

TABLE-US-00026 phytosterol isostearate 0.5 portion; Vitamin E acetate 1 portion; Cetyl stearyl alcohol 1 portion; Sucrose polystearate 2 portions; Dipalmitoyl hydroxyproline 1 portion; Rhodiola rosea Extract 0.1 portion

Phase B:

[0119]

TABLE-US-00027 Acrylates/C10-30 alkyl acrylate crosspolymer 0.1 portion; butanediol 5 portions; glycerin 2 portions; Sodium stearoyl glutamate 0.5 portion; disodium EDTA 0.1 portion; xanthan gum 0.1 portion; deionized water margin;

Phase C:

[0120] acrylamide/ammonia acrylate copolymer (and) Poly(isobutylene) 1.0 portion; (and) Polysorbate-20

Phase D:

[0121]

TABLE-US-00028 aminomethyl propanol 0.2 portion  1-methylhydantoin-2-imide 1.0 portion; creatine 0.2 portion; carnosine 0.2 portion; Glucosyl Hesperidin 0.5 portion; dipotassium glycyrrhetate 0.1 portion; Bifida ferment lysate 1.0 portion; Centella asiatica Extract 0.5 portion; Coenzyme Q10 capsule 0.5 portion; Opuntia Ficus-indica Stem Extract 1.0 portion; Hexapeptide-3 1.0 portion; Saussurea Involucrata Extract 0.1 portion; Panax notoginseng Root Extract 0.1 portion; Angelica sinensis Extract capsule 0.1 portion; preservatives 0.05 portion. 

[0122] The preparation process is as follows:

[0123] (1) All components in Phase A are mixed evenly, heated to 80° C., stirred to dissolve to obtain Phase A solution.

[0124] (2) Acrylates/C10-30 alkyl acrylate crosspolymer is added to deionized water, stirred to dissolve, then other raw materials in Phase B are added, heated to 80° C., stirred to dissolve to obtain Phase B solution.

[0125] (3) Phase A solution is added to Phase B solution, and then all components in Phase C are added, stirred to homogenize to be emulsified.

[0126] (4) The above mixture is stirred and cooled to 45° C., aminomethyl propanol is added, stirred to dissolve, and then other raw materials in Phase D are added, stirred and cooled to 30˜35° C.;

[0127] (5) A lotion is obtained, whose pH value is adjusted to 5.5˜6.5, and upon passing quality control, filled into the vessels.

Example 5

1. Preparation of Powder Part

[0128] The ingredients are:

TABLE-US-00029 Oligopeptide-1 1.0 portion; Ginseng saponin .sup. 5.0 portions; mannitol 20.0 portions..sup. 

[0129] The preparation process is as follows:

[0130] (1) All components are dissolved in an appropriate amount of deionized water, then the obtained solution is sterilized in an autoclave at 121° C., 0.1 Mpa for 30 mins.

[0131] (2) Distribute it into glass vials, and then put into the vacuum freeze drier.

[0132] (3) Vacuum freeze dried for 45 hours, to form a powder, then cap the vials.

2. Preparation of Aqueous Part

[0133] The ingredients are:

TABLE-US-00030 Glycyrrhiza glabra Root Extract 3.0 portions; Artemisia capillaris Flower Extract 3.0 portions; Radix Mori Albae Extract 2.0 portions; Zizyphus jujuba Fruit Extract 2.0 portions; Scutellaria baicalensis Root Extract 2.0 portions; hydrolyzed rice protein 5.0 portions; nicotinamide 3.0 portions; sodium hyaluronate 2.0 portions; butanediol 20.0 portions;  disodium EDTA 0.1 portion;.sup.  dipotassium glycyrrhetate 2.0 portions; panthenol 5.0 portions; preservatives 0.01 portion; .sup.  deionized water in an appropriate amount.

[0134] The molecular weight of the sodium hyaluronate is 300,000.

[0135] The preparation process is as follows:

[0136] (1) Sodium hyaluronate is added to the deionized water, stirred to dissolve.

[0137] (2) Other components are added, stirred to dissolve;

[0138] (3) An aqueous part is obtained, whose pH value is adjusted to 5.5˜7.0, upon passing quality examination, filled into vessels.

3. Preparation of a Lotion

[0139] The ingredients are:

Phase A:

[0140]

TABLE-US-00031 phytosterol isostearate 0.5 portion;.sup.  Vitamin E acetate .sup. 3 portions; Rhodiola rosea Extract 2.0 portions .sup.  Cetyl stearyl alcohol 1 portion; Sucrose polystearate .sup. 2 portions; Dipalmitoyl hydroxyproline 1 portion;

Phase B:

[0141] Acrylates/C10-30 alkyl acrylate crosspolymer 0.1 portion;

TABLE-US-00032 butanediol  .sup. 5 portions; glycerin  .sup. 2 portions; Sodium stearoyl glutamate 0.5 portion; disodium EDTA 0.1 portion; xanthan gum 0.1 portion; deionized water margin;

Phase C:

[0142] acrylamide/ammonia acrylate copolymer (and) Poly(isobutylene) 1.0 portion; (and) Polysorbate-20

Phase D:

[0143]

TABLE-US-00033 aminomethyl propanol 0.2 portion; 1-methylhydantoin-2-imide 1.0 portion; creatine .sup. 2.0 portions; carnosine .sup. 2.0 portions; Glucosyl Hesperidin .sup. 5.0 portions; dipotassium glycyrrhetate 0.1 portion; Bifida ferment lysate 10.0 portions;.sup.  Hexapeptide-3 .sup. 5.0 portions Centella asiatica Extract .sup. 3.0 portions; Coenzyme Q10 capsule 0.5 portion; Opuntia Ficus-indica Stem Extract 1.0 portion; Saussurea Involucrata Extract 0.1 portion; Panax notoginseng Root Extract 0.1 portion; Angelica sinensis Extract capsule 0.1 portion; preservatives. 0.05 portion. 

[0144] The preparation process as follows:

[0145] (1) All components in Phase A are mixed evenly, heated to 80° C., stirred to dissolve to obtain Phase A solution.

[0146] (2) Acrylates/C10-30 alkyl acrylate crosspolymer is added to deionized water, stirred to dissolve, then other raw materials in Phase B are added, heated to 80° C., stirred to dissolve to obtain Phase B solution.

[0147] (3) Phase A solution is added to Phase B solution, and all components in Phase C are added, stirred to homogenize to be emulsified.

[0148] (4) The above mixture is stirred and cooled to 45° C., aminomethyl propanol is added, stirred to dissolve, and then other components in Phase D are added, stirred and cooled to 30˜35° C.;

[0149] (5) A lotion is obtained, whose pH value is adjusted to 5.5˜6.5, upon passing quality examination, the lotion filled in vessels.

Comparative Product

[0150] The comparative product used in the present invention is a skin care product available in the prior art, which has a composition as follows (portions by weight):

TABLE-US-00034 PPG-3 Benzyl ether myristate  .sup.  2~5 portions Polyglycerin-3 methylglucose distearate  .sup.  2~5 portions Hydrogenated Poly(isobutylene)  .sup.  2~5 portions Palmitoyl Pentapeptide-3  .sup.  2~5 portions Polyglycerin-3 methylglucose distearate  .sup.  1~3 portions Oat Extract  .sup.  1~3 portions hexadecanol - octadecanol  .sup.  1~3 portions Glycerin monosterate  .sup.  1~3 portions bisabolol 0.1~0.5 portion Butcher's Broom Root Extract 0.1~0.3 portion Centella asiatica Extract 0.1~0.5 portion panthenol 0.1~0.5 portion Calendula officinalis L. Extract 0.1~0.5 portion Hydrolyzed yeast protein 0.1~0.5 portion Aesculus hippocastanum Extract 0.1~0.5 portion Monoammonium glycyrrhizinate 0.1~0.5 portion BOSWELLIA SERRATA Extract 0.1~0.3 portion carnosine 0.1~0.5 portion xanthan gum 0.1~0.5 portion Radix Ginseng Extract 0.1~0.5 portion Ganoderma lucidum Extract 0.1~0.5 portion Boswellia carteri Extract 0.1~0.5 portion Oligopeptide-1 0.1~0.5 portion preservatives 0.1~0.2 portion

[0151] For all the embodiments described above, the three parts of the composition are separately prepared and stored in separate containers until being used by users. In use, first mix the powder part in the aqueous part in a weight ratio between 1:50 and 1:500, preferably 1:100, and apply the mixture to the skin under gentle massage. Then, the emulsion part (in an amount roughly equal to the mixture of the power and aqueous part) is applied to the skin. The product is to be applied twice a day in the morning and the evening, respectively.

Testing Conducted and Effects Observed

[0152] In order to confirm the intended effects of the present invention, testing was conducted on female volunteers who had various undesirable skin conditions or symptoms and voluntarily enrolled for the trial. For each particular skin conditions (see below), three groups of volunteers, with 50 or more in each group, were assigned to use the products of embodiment 1, embodiment 2 and comparative prior art (described above), respectively. For each of the following skin conditions, the products were applied to the facial skin twice a day for 4 weeks (about 3% volunteers terminated the use due to side effects during the 4-week trial period). The application of the product on facial skin was conducted in a manner that a person normally uses a cosmetic product. About one gram of the product was used each time with a ratio of 1:100:100 among the power part, aqueous part and emulsion part (first applying the mixture of power and aqueous parts and then applying the emulsion part with a gentle massage in between). At the end of each week during the trial, each volunteer was asked about what was her degree of satisfaction with the product on a scale from 1 to 5 and how effective she found the product on relieving a particular skin condition on a scale from 1 to 3 (1 means no effect, 2 means some effect, and 3 means significant effect). The following skin conditions/symptoms were tried:

[0153] 1. Facial wrinkles/fine lines. The result was shown in FIG. 2(a).

[0154] 2. Rough skin. The result was shown in FIG. 2(b).

[0155] 3. Dry skin/dehydration. The result was shown in FIG. 2(c).

[0156] 4. Flabby skin/lack of elasticity. The result was shown in FIG. 2(d).

[0157] 5. Dull skin tone/lack of gloss. The result was shown in FIG. 2(e).

[0158] 6. Large skin pore size. The result was shown in FIG. 2(f).

[0159] 7. Variated skill colors/lack of color uniformity. The result was shown in FIG. 2(g).

[0160] 8. Oily skin. The result was shown in FIG. 2(h).

[0161] 9. Skin with colored spots. The result was shown in FIG. 2(i).

[0162] 10. Pigment sediment. The result was shown in FIG. 2(j).

[0163] 11. Scar left after acne. The result was shown in FIG. 2(k).

[0164] Other skin conditions, such as, reddish-prone skin, couperose-prone skin, scurf-prone skin and allergic sensitive skin, were also tried but the data are not shown here as there were not enough volunteers enrolled for the trial.

[0165] FIG. 1 is the summary of the overall satisfactory rate of each product by the participating volunteers (1, 2 and c refers to products of embodiment 1 embodiment 2 and the comparative prior art product, respectively). As can be seen from FIG. 1, comparing with the existing product available in the art (c), both embodiments (1 and 2) of the present invention demonstrated a superior result. At the end of the 4 week trial, both received higher satisfactory rates, 3.81 and 3.58, respectively, comparing to 3.38 for the prior art product. More significantly, the longer the present invention product was used, the result was better. By comparison, the prior art product peaked at week 3 and continued use had a declined satisfaction. The data suggest that not only the products of the present invention have quicker and better effects from onset but also are better suited for long-term use.

[0166] FIG. 2 shows the effects on specific skin conditions/symptoms tried. For example, FIG. 2(a) relates to the condition of facial wrinkles and appearance of fine lines. The left-side curves show that volunteers in the embodiment 1 group (.diamond-solid.) rated the effectiveness at 1.29 (average) after the first week, 1.69 after the second week, 1.79 after the week and 1.90 after the fourth week. The corresponding data for the embodiment 1 group (.square-solid.) are 1.31, 1.49, 1.64 and 180 and for the prior art group (.box-tangle-solidup.), the data are 1.23, 1.37, 1.58 and 1.67. For effectiveness rate, 1 means no effect, 2 means some effect, and 3 means significant effects. Understandably, for a cosmetic product, the effectiveness rarely reaches 3. The right-side table shows that Embodiment 1 has an onset time of 13.3 days, which refers to the average time when the volunteers observed at least some effects. The onset time is 13.5 days for Embodiment 2 and 15.3 days for the comparative product. In the Embodiment 1 group, 29% volunteers observed at least some effect (i.e., giving an effectiveness rate of either 2 or 3) at week 1, 62% at week 2, 69% at week 3 and 76% at week 4. The corresponding percentages for Embodiment 2 are 31%, 49%, 58% and 67%. For comparison, the data for the prior art product are 21%, 35%, 53% and 67%. Similar treads can be found in FIG. 2(b)-(k), and it shows that for all the skin conditions/symptoms tried, the products of the present invention had consistently achieved better results than the prior art comparative product in terms of the onset time, the percentage and the degree of effectiveness.

[0167] Although not wishing to be bound to any particular theory, the inventors believe that the product of the present invention may achieve its beneficial effects on skin conditions by regulating the immunity and delaying the aging process of skin induced by the sun light. This mechanism was at least part of the consideration in selecting the various ingredients, many of which are derived from natural sources and used in the traditional medicine showing effects in regulating immunity. This may serve as a guideline in modifying the embodiments disclosed herewith and such modifications may achieve similar effects without departing from the spirit of the present invention.

[0168] While there have been described and pointed out fundamental novel features of the invention as applied to a preferred embodiment thereof, it will be understood that various omissions and substitutions and changes, in the form and details of the embodiments illustrated, may be made by those skilled in the art without departing from the spirit of the invention. The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims